Jack J Chen

Summary

Affiliation: Loma Linda University
Country: USA

Publications

  1. ncbi request reprint Essential tremor: diagnosis and treatment
    Jack J Chen
    Department of Pharmacy Practice, College of Pharmacy, Western University of Health Sciences, Pomona, California 91766 1854, USA
    Pharmacotherapy 23:1105-22. 2003
  2. ncbi request reprint Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease
    Jack J Chen
    Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Pharmacotherapy 29:1452-67. 2009
  3. doi request reprint Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer
    Jack J Chen
    School of Pharmacy, Shryock Hall 225, Loma Linda University, Loma Linda, CA 92350, USA
    Pharmacotherapy 33:304-18. 2013
  4. doi request reprint Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature
    Jack J Chen
    Movement Disorders Clinic, Schools of Medicine and Pharmacy, Loma Linda University, 11262 Campus Street, Loma Linda, CA 92350, USA
    Clin Ther 34:1487-504. 2012
  5. doi request reprint The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Jack J Chen
    Department of Neurology, School of Medicine and Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, CA, USA
    J Clin Pharmacol 52:620-8. 2012
  6. ncbi request reprint Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
    Jack J Chen
    Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Clin Ther 29:1825-49. 2007
  7. ncbi request reprint Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment
    Jack J Chen
    Loma Linda University, 11262 Campus Street, Loma Linda, CA 92350, USA
    Am J Manag Care 16:S87-93. 2010
  8. ncbi request reprint Pharmacotherapy for Parkinson's disease
    Jack J Chen
    Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, CA 92350, USA
    Pharmacotherapy 27:161S-173S. 2007
  9. ncbi request reprint Implications for managed care for improving outcomes in Parkinson's disease: balancing aggressive treatment with appropriate care
    Jack J Chen
    Department of Pharmacotherapy and Outcomes Science, Department of Neurology, School of Medicine, Loma Linda University, Loma Linda, CA, USA
    Am J Manag Care 17:S322-7. 2011
  10. ncbi request reprint Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors
    Jack J Chen
    Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Drugs Aging 24:663-80. 2007

Detail Information

Publications21

  1. ncbi request reprint Essential tremor: diagnosis and treatment
    Jack J Chen
    Department of Pharmacy Practice, College of Pharmacy, Western University of Health Sciences, Pomona, California 91766 1854, USA
    Pharmacotherapy 23:1105-22. 2003
    ..A treatment algorithm is provided to guide clinicians in the management of patients with essential tremor...
  2. ncbi request reprint Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease
    Jack J Chen
    Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Pharmacotherapy 29:1452-67. 2009
    ....
  3. doi request reprint Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer
    Jack J Chen
    School of Pharmacy, Shryock Hall 225, Loma Linda University, Loma Linda, CA 92350, USA
    Pharmacotherapy 33:304-18. 2013
    ....
  4. doi request reprint Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature
    Jack J Chen
    Movement Disorders Clinic, Schools of Medicine and Pharmacy, Loma Linda University, 11262 Campus Street, Loma Linda, CA 92350, USA
    Clin Ther 34:1487-504. 2012
    ..This review focuses on the use of TBZ in various hyperkinetic movement disorders, which are considered "rare" or "orphan" diseases, to help practitioners better understand its clinical role and use...
  5. doi request reprint The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Jack J Chen
    Department of Neurology, School of Medicine and Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, CA, USA
    J Clin Pharmacol 52:620-8. 2012
    ....
  6. ncbi request reprint Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
    Jack J Chen
    Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Clin Ther 29:1825-49. 2007
    ..Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson's disease (PD)...
  7. ncbi request reprint Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment
    Jack J Chen
    Loma Linda University, 11262 Campus Street, Loma Linda, CA 92350, USA
    Am J Manag Care 16:S87-93. 2010
    ..None has demonstrated irrefutable and enduring disease-modifying qualities, although the best available clinical evidence appears most promising for rasagiline...
  8. ncbi request reprint Pharmacotherapy for Parkinson's disease
    Jack J Chen
    Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, CA 92350, USA
    Pharmacotherapy 27:161S-173S. 2007
    ..Surgery may be considered when patients need additional symptomatic control or are experiencing severe motor complications despite pharmacologically optimized therapy...
  9. ncbi request reprint Implications for managed care for improving outcomes in Parkinson's disease: balancing aggressive treatment with appropriate care
    Jack J Chen
    Department of Pharmacotherapy and Outcomes Science, Department of Neurology, School of Medicine, Loma Linda University, Loma Linda, CA, USA
    Am J Manag Care 17:S322-7. 2011
    ..In addition to evaluation of symptomatic therapies for PD, attention to advances in disease-modifying therapies and to management of nonmotor symptoms should be an integral component of PD surveillance in the managed care environment...
  10. ncbi request reprint Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors
    Jack J Chen
    Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Drugs Aging 24:663-80. 2007
    ..The favourable safety profile of rasagiline in the elderly and its once-daily formulation may maximise drug adherence and improve outcomes...
  11. doi request reprint Pharmacologic safety concerns in Parkinson's disease: facts and insights
    Jack J Chen
    Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, CA 92350, USA
    Int J Neurosci 121:45-52. 2011
    ..Concerns about ST or hypertensive crisis should not preclude or restrict clinicians from using MAO-B inhibitors in patients with PD...
  12. ncbi request reprint Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease
    Jack J Chen
    School of Pharmacy, Loma Linda University, 11262 Campus Street, Loma Linda, CA 92350, USA
    Am J Health Syst Pharm 63:915-28. 2006
    ..The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed...
  13. ncbi request reprint Nonparkinsonism movement disorders in the elderly
    Jack J Chen
    School of Pharmacy, Loma Linda University, California 92350, USA
    Consult Pharm 21:58-71. 2006
    ..The primary objective of this article is to review the clinical presentation and pharmacologic management of essential tremor and tardive dyskinesia...
  14. ncbi request reprint A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease
    Jack J Chen
    Movement Disorders Center and School of Pharmacy, Loma Linda University, 1162 Campus Street West Hall, Loma Linda, CA 92350, USA
    Clin Ther 27:1710-24. 2005
    ....
  15. ncbi request reprint Monoamine oxidase-B inhibition in the treatment of Parkinson's disease
    Hubert H Fernandez
    Movement Disorders Center, University of Florida, McKnight Brain Institute, Gainesville, FL 32610, USA
    Pharmacotherapy 27:174S-185S. 2007
    ..A third agent with MAO-B inhibition properties, safinamide, is in phase III development. Although not yet approved, safinamide may offer the added advantage of combined MAO-B and dopamine reuptake inhibition...
  16. ncbi request reprint Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease
    Jack J Chen
    Movement Disorders Center, Loma Linda University, Loma Linda, CA, USA
    J Clin Pharmacol 45:878-94. 2005
    ..Thus, in addition to symptomatic benefits, rasagiline offers the promise of clinically relevant neuroprotection...
  17. ncbi request reprint Monamine oxidase inhibitors: current and emerging agents for Parkinson disease
    Hubert H Fernandez
    Movement Disorders Center, Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, FL 32610, USA
    Clin Neuropharmacol 30:150-68. 2007
    ..Unlike selegiline, rasagiline is an aminoindan derivative with no amphetamine metabolites. A randomized clinical trial is underway to confirm preclinical and preliminary clinical data suggesting rasagiline has disease-modifying effects...
  18. ncbi request reprint Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease
    Crystal D Obering
    School of Pharmacy, University of Missouri Kansas City, and the Department of Pharmacy, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri 64108, USA
    Pharmacotherapy 26:840-52. 2006
    ..These potential effects can be managed with antiemetic prophylaxis and appropriate determination of the therapeutic rescue dose...
  19. ncbi request reprint Depression in Parkinson's disease: identification and management
    Jack J Chen
    Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, California
    Pharmacotherapy 33:972-83. 2013
    ....
  20. ncbi request reprint Anxiety, depression, and psychosis in Parkinson's disease: unmet needs and treatment challenges
    Jack J Chen
    Department of Pharmacy Practice, Western University of Health Sciences, 309 East Second Street, Pomona, CA 91766, USA
    Neurol Clin 22:S63-90. 2004
  21. ncbi request reprint A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A
    Jack J Chen
    J Clin Psychiatry 66:267-8. 2005